No April Fool’s Joke: MannKind’s Afrezza Flies Through FDA Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Inhaled insulin gains advisory committee endorsement in both type 1 and 2 populations. Given efficacy questions and potential safety concerns, panelists suggest patients who would most benefit include those with limited ability to self-inject and who need additional glycemic control in between meals.